Prot #NU MSK12H10: A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date7/9/14 → 7/9/17

Funding

  • Genentech, Inc (Prot #NU MSK12H10 // Prot #NU MSK12H10)
  • Memorial Sloan Kettering Cancer Center (Prot #NU MSK12H10 // Prot #NU MSK12H10)